Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Forced Transdifferentiation01:28

Forced Transdifferentiation

Transdifferentiation, also known as lineage reprogramming, was first discovered by Selman and Kafatos in 1974 in silkmoths. They observed that the moths’ cuticle-producing cells transformed into salt-producing cells. Many such cases of natural transdifferentiation occur in organisms. In humans, pancreatic alpha cells can become beta cells. In newts, the loss of the eye’s lens causes the pigmented epithelial cells to transdifferentiate into the lens cells.
Artificial transdifferentiation occurs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individualised treatment effect prediction: the benefit of initial biological treatment in early rheumatoid arthritis.

EULAR rheumatology open·2026
Same author

Five years of the Digital Rheumatology Network: insights and future directions.

EULAR rheumatology open·2026
Same author

Recent developments in the use of biomarkers as diagnostic tools in patients with systemic lupus erythematosus: a narrative review.

EULAR rheumatology open·2026
Same author

A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial.

Arthritis research & therapy·2025
Same author

HandScan criteria versus ACR/EULAR Boolean remission as treatment target in early rheumatoid arthritis: results of a randomized controlled trial.

Rheumatology advances in practice·2025
Same author

A retrospective study on beta-blocker use and outcomes in hematopoietic stem cell transplant patients.

PeerJ·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

Stem cell transplantation in systemic sclerosis.

Jacob M van Laar1, Keith Sullivan

  • 1aInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK bDivision of Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.

Current Opinion in Rheumatology
|September 20, 2013
PubMed
Summary
This summary is machine-generated.

Autologous stem cell transplantation improves systemic sclerosis symptoms and survival, but carries treatment-related mortality risks. Careful patient selection and screening are crucial for successful outcomes in this severe autoimmune disease.

More Related Videos

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration
10:03

Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration

Published on: January 20, 2014

Related Experiment Videos

Last Updated: May 7, 2026

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration
10:03

Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration

Published on: January 20, 2014

Area of Science:

  • Immunology
  • Rheumatology
  • Hematology

Background:

  • Systemic sclerosis is a severe autoimmune disease with limited treatment options.
  • Autologous stem cell transplantation (ASCT) has emerged as a potential therapeutic strategy.

Purpose of the Study:

  • To review recent clinical and mechanistic studies on ASCT for systemic sclerosis.
  • To discuss the implications of these findings for clinical practice.

Main Methods:

  • Retrospective analyses of ASCT cohorts.
  • Randomized controlled trials comparing ASCT with cyclophosphamide.
  • Mechanistic studies on immune cell shifts post-ASCT.
  • Evaluation of thoracic high-resolution CT (HRCT) and serum markers for lung fibrosis.

Main Results:

  • ASCT significantly improved skin thickening, lung function, and quality of life.
  • ASCT demonstrated superior efficacy and survival benefit compared to cyclophosphamide in severe systemic sclerosis.
  • Treatment-related mortality ranged from 6-17%, necessitating cardiopulmonary screening.
  • Mechanistic studies revealed significant immune cell modulation post-ASCT.
  • ASCT led to reduced lung fibrosis markers and HRCT abnormalities.

Conclusions:

  • ASCT is an effective treatment for severe systemic sclerosis, offering significant clinical benefits.
  • Treatment-related mortality and toxicity are important considerations.
  • Rigorous patient selection and comprehensive cardiopulmonary screening are essential for optimizing ASCT outcomes.